Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 146
- News
ACMD Reveals It Hasn’t Examined Cannabis Evidence For 14 Years As Signs Of UK’s ‘Appetite For Reform’ Grows
LAST week saw the British Government reinstate its hardline position on drug policy, as Policing Minister Kit Malthouse announced new headline-grabbing policies aimed at cracking down on football fans and ‘middle class’ drug users.
- Opinion
European Cannabis Industry ‘Potentially An Even Bigger Opportunity’ Than The US, And Investors Should ‘Wake Up To The Opportunities In Their Own Backyard’
NORTH American investment in the European cannabis industry has grown at pace over the last few years, with hundreds of millions in capital flooding into the region from across the Atlantic.
- Markets & Stocks
European Cannabis Stocks Roundup: Aurora Stocks Jump On EU Medical Market Growth Despite $1bn Loss
IT’S been a jam-packed week for the global cannabis industry as a host of companies including Aurora, Halo Collective, Dancann Pharma, Yooma Wellness and Intercure, among others, reported quarterly results.
- News
Yooma Wellness Shares Return To Trading As It Reports $33m Loss For 2021
YOOMA Wellness has released its Q4 and full year results for 2021 two weeks behind schedule, seeing its shares reinstated on the Aquis Exchange after being suspended due to the delay.
- News
Intercure Posts More Record Results But Says It ‘Could Do So Much More’ If It Had More Supply
INTERCURE has released another set of ‘all time record quarterly’ results, seeing both revenues and profits skyrocket year-on-year.
- News
Chill Brands Targets Near £4m Capital Raise To Fund Fresh Strategy & £1.3m Chill.com Domain
CHILL Brands’ shareholders have voted in favour of plans for a new £3.5m fundraise alongside a separate £484,000 open share offer to ‘ensure the company is well capitalised and able to grow’.
- CBD Market
Cellular Goods Makes More Major Changes To Board In First Update Since Ingestibles Were Pulled (UPDATED)
CELLULAR Goods has released its first significant update since announcing that its ingestibles products were not legally allowed to be sold in the UK.
- Markets & Stocks
European Cannabis Stocks Review: Akanda Dives Over 80% & Celadon Suffers After Reporting Huge Rise In Losses
This week was another difficult week for London Stock Exchange (LSE) listed cannabis companies, with every one of BusinessCann’s tracked stocks reporting declines, including the recent AIM debutante Celadon Pharmaceuticals.
- Adult-Use
Is German Oversupply Hampering Growth Of Its Medical Cannabis Industry?
GERMANY is continuing to see cannabis companies from across the globe pile into its medical cannabis market in the hopes of securing their piece of the pie.
- Uncategorized
Behindert ein Überangebot in Deutschland das Wachstum der medizinischen Cannabisindustrie?
In Deutschland drängen weiterhin Cannabisunternehmen aus der ganzen Welt auf den medizinischen Cannabismarkt, in der Hoffnung, sich ein Stück vom Kuchen zu sichern.
- Press releases
Aurora Launches New EU GMP Extracts To Expand Therapy Options For Cannabis Patients In The United Kingdom
AURORA Cannabis, a pioneer and global leader in the medical cannabis industry, has launched three new cannabis extracts for patients in the United Kingdom.
- Adult-Use
Grow Group Plans IPO In ‘Next 12 Months’ Following German Expansion
GROW Group told BusinessCann back in 2020 that it was raising £6m in capital to fund its expansion across Europe, setting its sights on the German medical cannabis opportunity.











